Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.52 |
| ▸ | PNMT | P11086 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303980 | 0.84 | IDO1 (0.50) | IDO1FDPSPNMTTAAR1SIGMAR1 | |
| SCHEMBL9917351 | 0.83 | ESR1 (0.43) | IDO1FDPSESR1CYP1A2TSHR | |
| SCHEMBL11251872 | 0.83 | FDPS (0.58) | IDO1FDPSPNMTTAAR1SIGMAR1 | |
| SCHEMBL20609656 | 0.83 | ESR1 (0.43) | IDO1FDPSPNMTTAAR1ESR1 | |
| SCHEMBL12215710 | 0.83 | SLC6A2 (0.61) | IDO1FDPSPNMTTAAR1SIGMAR1 | |
| SCHEMBL9917301 | 0.83 | CYP3A4 (0.48) | IDO1FDPSESR1SIGMAR1SLC6A2 | |
| SCHEMBL4452262 | 0.81 | CA2 (0.54) | FDPSESR1CYP1A2TSHRMEN1 | |
| SCHEMBL11955043 | 0.81 | ESR1 (0.42) | IDO1FDPSPNMTESR1SLC6A2 | |
| SCHEMBL21662215 | 0.81 | ESR1 (0.42) | IDO1FDPSPNMTTAAR1ESR1 | |
| SCHEMBL9917330 | 0.81 | ESR1 (0.42) | IDO1FDPSPNMTTAAR1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-11684609-B2 | Compounds and methods for treating an epileptic disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-7488827-B2 | Muscle relaxants; respiratory system disorders; asthma;COPD; emphysema; bronchitis | GLAXO GROUP LIMITED (GB) | 2009-02-10 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070093544-A1 | 1-((4-Tert-butylcyclohexyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl-amino-)-N-1H-tetrazole-5-yl-indane-5-carboxamide; glucagon receptor antagonists; antidiabetic agents; type 2 diabetes mellitus; insulin resistance; gluconeogenesis inhibitors; lowering rate of hepatic glucose output; hypoglycemic agents | MERCK SHARP & DOHME LLC | 2007-04-26 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | IDO1 2785/4885FDPS 3729/4885PNMT 215/4885 |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | IDO1 3923/4885FDPS 1498/4885PNMT 3893/4885 |
| US-20070093544-A1 | 1-((4-Tert-butylcyclohexyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl-amino-)-N-1H-tetrazole-5-yl-indane-5-carboxamide; glucagon receptor antagonists; antidiabetic agents; type 2 diabetes mellitus; insulin resistance; gluconeogenesis inhibitors; lowering rate of hepatic glucose output; hypoglycemic agents | GPR119, GLP1R, INSR | IDO1 1621/4885FDPS 2908/4885PNMT 1520/4885 |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | IDO1 2418/4885FDPS 4674/4885PNMT 2923/4885 |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | IDO1 947/4885FDPS 2008/4885PNMT 102/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | IDO1 3923/4885FDPS 1498/4885PNMT 3893/4885 |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP1 | IDO1 1523/4885FDPS 1287/4885PNMT 3802/4885 |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | IDO1 2418/4885FDPS 4674/4885PNMT 2923/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | IDO1 2403/4885FDPS 2778/4885PNMT 1911/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | IDO1 3963/4885FDPS 2992/4885PNMT 2581/4885 |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA5, CHRNA2 | IDO1 1240/4885FDPS 3826/4885PNMT 348/4885 |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | IDO1 2418/4885FDPS 4674/4885PNMT 2923/4885 |
| US-11684609-B2 | Compounds and methods for treating an epileptic disorder | GABRE, SLC6A1, GABBR1 | IDO1 2818/4885FDPS 1416/4885PNMT 124/4885 |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | IDO1 2659/4885FDPS 3925/4885PNMT 1370/4885 |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | IDO1 2785/4885FDPS 3729/4885PNMT 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.